Clinical evaluation demonstrates therapeutic outcomes in patients with heterozygous familial hypercholesterolemia, highlighting the efficacy of targeted drug program regimens.
Key Points
To assess clinical outcomes and therapeutic efficacy in patients diagnosed with heterozygous familial hypercholesterolemia enrolled in the B101 drug treatment program.
Evaluated patients diagnosed with heterozygous familial hypercholesterolemia receiving targeted therapeutic regimens within the specialized B101 reimbursement drug program.
Monitored treatment response, tolerance, and lipid management parameters under standardized clinical protocols.
Characterizes therapeutic response rates and lipid profile improvements achieved under specialized drug program administration.
Demonstrates the real-world management and clinical trajectory of severe inherited hypercholesterolemia receiving advanced pharmacotherapy.